Home  |  Search  |  Info Publications  |  Dr. Shelton's Pearls  |  Population Reports  |  Español/Francais

Shopping Basket

	Injectable Contraceptives: Tools for Providers
December 2006 Issue No. 8	The INFO Project • Johns Hopkins Bloomberg School of Public Health • Center for Communication Programs • 111 Market Place, Suite 310 • Baltimore, Maryland 21202, USA • 410-659-6300 • 410-659-6266 (fax) • www.infoforhealth.org • infoproject@jhuccp.org

Injectable Contraceptives: Tools for Providers Table 2. Helping Clients Make a Well-Informed Choice of Injectable Contraceptives Table 3. Helping Clients Be Informed Users of Injectable Contraceptives Checklist for Giving Intramuscular Contraceptive Injections Checklist for Screening Clients Who Want to Initiate DMPA (or NET-EN), part a Checklist for Screening Clients Who Want to Initiate DMPA (or NET-EN), part b Sources Subscription and Ordering Information Credits

Sources

This bibliography includes citations to the materials most helpful in the preparation of this report. In the text, reference numbers for these citations appear in italics. The complete bibliography for this report and the companion Population Reports issue can be found at: http://www.populationreports.org/k6/. The links included in this report were up-to-date at the time of publication.

 

7. ARIAS, R.D., JAIN, J.K., BRUCKER, C., ROSS, D., and RAY, A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. Contraception 74(3): 234–238. Sep. 2006.

10. BAETEN, J.M., NYANGE, P.M., RICHARDSON, B.A., LAVREYS, L., CHOHAN, B., MARTIN, H.L., JR., MANDALIYA, K., NDINYA-ACHOLA, J.O., BWAYO, J.J., and KREISS, J.K. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. American Journal of Obstetrics and Gynecology 185(2): 380–385. Aug. 2001.

15. BEKSINSKA, M.E., SMIT, J.A., KLEINSCHMIDT, I., FARLEY, T.M., and MBATHA, F. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception 71(3): 170–175. Mar. 2005.

16. BELSEY, E.M. The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception 38(2): 207–225. Aug. 1988.

17. BELSEY, E.M., MACHIN, D., and D'ARCANGUES, C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34(3): 253–260. Sep. 1986.

23. BONNY, A.E., ZIEGLER, J., HARVEY, R., DEBANNE, S.M., SECIC, M., and CROMER, B.A. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Archives of Pediatrics & Adolescent Medicine 160(1): 40–45. Jan. 2006.

25. BOYLE, P., CHILVERS, C., FERRAZ, E., HULKA, B., KING, R., LA VECCHIA, C., PETITTI, D., LUMBIGANON, P., SKEGG, D., and THOMAS, D. Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting. Bulletin of the World Health Organization 71(6): 669–676. 1993.

30. CANTO DE CETINA, T.E., CANTO, P., and ORDONEZ LUNA, M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 63(3): 143–146. Mar. 2001.

48. DRAPER, B.H., MORRONI, C., HOFFMAN, M., SMIT, J., BEKSINSKA, M., HAPGOOD, J., and VAN DER MERWE, L. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database of Systematic Reviews 3: CD005214. Jul. 19, 2006.

62. GLASIER, A.F., SMITH, K.B., VAN DER SPUY, Z.M., HO, P.C., and CHENG, L. Amenorrhea associated with contraception: An international study on acceptability. Contraception 67(1): 1–8. Jan. 2003.

75. HUBACHER, D., GOCO, N., GONZALEZ, B., and TAYLOR, D. Factors affecting continuation rates of DMPA. Contraception 60(6): 345–351. Dec. 1999.

80. HUTIN, Y., HAURI, A., CHIARELLO, L., CATLIN, M., STILWELL, B., GHEBREHIWET, T., and GARNER, J. Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections. Bulletin of the World Health Organization 81(7): 491–500. 2003. (Available: http://www.who.int/bulletin/volumes/81/7/en/Hutin0703.pdf)

83. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF). Directory of hormonal contraceptives. (http://contraceptive.ippf.org/) IPPF, Jan. 26, 2006.

87. JAIN, J., JAKIMIUK, A.J., BODE, F.R., ROSS, D., and KAUNITZ, A.M. Contraceptive efficacy and safety of DMPA-SC. Contraception 70(4): 269–275. Oct. 2004.

99. LANDE, R.E. New era for injectables. Population Reports, Series K, No. 5. Baltimore, Johns Hopkins School of Public Health, Population Information Program, Aug. 1995. 31 p.

100. LEI, Z.W., WU, S.C., GARCEAU, R.J., JIANG, S., YANG, Q.Z., WANG, W.L., and VANDER MEULEN, T.C. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 53(6): 357–361. Jun. 1996.

130. PARDTHAISONG, T. Return of fertility after use of the injectable contraceptive Depo Provera: Up-dated data analysis. Journal of Biosocial Science 16(1): 23–34. Jan. 1984.

135. PAUL, C., SKEGG, D.C., and WILLIAMS, S. Depot medroxyprogesterone acetate: Patterns of use and reasons for discontinuation. Contraception 56(4): 209–214. Oct. 1997.

190. TRUSSELL, J. Contraceptive efficacy. In: Contraceptive Technology. 18th ed. New York, Ardent Media, 2004. p. 773–845.

198. UPADHYAY, U.D. Informed choice in family planning: Helping people decide. Population Reports Series J, No. 50. Baltimore, Johns Hopkins Bloomberg School of Public Health, Population Information Program, Spring 2001. 39 p. (Available: http://www.infoforhealth.org/pr/j50edsum.shtml)

202. WORLD HEALTH ORGANIZATION (WHO). Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception 28(1): 1–20. Jul. 1983.

212. WORLD HEALTH ORGANIZATION (WHO). Medical eligibility criteria for contraceptive use. 3rd ed. Geneva, WHO, Department of Reproductive Health and Research, 2004. 168 p. (Available: http://www.who.int/reproductive-health/publications/mec/index.htm)

215. WORLD HEALTH ORGANIZATION (WHO). Selected practice recommendations for contraceptive use. 2nd ed. Geneva, WHO, Department of Reproductive Health and Research, 2004. 170 p. (Available: http://www.who.int/reproductive-health/publications/spr/spr.pdf)

216. WORLD HEALTH ORGANIZATION (WHO). WHO statement on hormonal contraception and bone health. Weekly Epidemiological Record 80(35): 302–304. Sep. 2005.

*219. WORLD HEALTH ORGANIZATION (WHO) and JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH (JHSPH) CENTER FOR COMMUNICATION PROGRAMS. Family planning: A global handbook for providers. JHSPH, The INFO Project, and WHO (forthcoming).

220. WORLD HEALTH ORGANIZATION (WHO), SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION, and TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate: Bleeding patterns and side effects. Contraception 17(5): 395–406. May 1978.

  
Back to top